29.20
-0.25 (-0.85%)
| Previous Close | 29.45 |
| Volume | 4,365,750 |
| Avg. Volume (3M) | 2,762,359 |
| Market Cap | 5,942,986,752 |
| Price / Sales | 1.94 |
| Price / Book | 1.59 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2026 |
| TTM Dividend Yield | 27.84% |
| Profit Margin | 32.75% |
| Operating Margin (TTM) | 46.94% |
| Diluted EPS (TTM) | -0.760 |
| Quarterly Revenue Growth (YOY) | 13.40% |
| Quarterly Earnings Growth (YOY) | 226.20% |
| Total Debt/Equity (MRQ) | 3.13% |
| Current Ratio (MRQ) | 0.620 |
| Operating Cash Flow (TTM) | 96.00 M |
| Levered Free Cash Flow (TTM) | 227.12 M |
| Return on Assets (TTM) | 29.34% |
| Return on Equity (TTM) | 6.32% |
News Mood
AIStockmoo Score
| Value 38% | 0.0 |
| Low debt. Strong profitability. Thin short-term liquidity. Positive cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Earnings Trend info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 38% | -2.7 |
| No clear trend over the past year. Far below its 52-week high. info | |
| In a downtrend: the price is below its moving averages, and they are falling. It is close to them. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 25% | 0.7 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Holdings' Sentiment info | NA |
| Smart Money | NA |
| Insider Activity info | NA |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Below its medium-term trend line. info | |
| Price is low against its 52-week average. Up over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| Price is near resistance. info | |
| Final Score | -0.96 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Supernus, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| SUPN | 6 B | 27.84% | - | 1.59 | -1.0 |
| ANIP | 2 B | - | 13.74 | 2.57 | -0.1 |
| COLL | 783 M | - | 23.13 | 2.72 | 0.1 |
| TKNO | 480 M | - | - | - | 0.8 |
| AQST | 435 M | - | - | - | -1.7 |
| TLRY | 279 M | - | - | 0.200 | -2.2 |
Select this tab to load the latest available analysis.
|
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 2.06% |
| % Held by Institutions | 61.81% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Nov 2026 | Yahoo Finance |
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus, Inc., will… |
| 10 Nov 2026 | Yahoo Finance |
Supernus (SUPN) Stock Still Looks Undervalued As Its 127% 5 Year Run Continues
Supernus has had a volatile few years, and with the share price at US$27.62 after a sharp pullback, the key issue is whether that price still lines up with what its earnings can reasonably support. Over the past 5 years, Supernus has delivered a 127.5% share price gain. This puts real weight on the… |
| 09 Nov 2026 | Yahoo Finance |
Supernus undervalued after Indivior merger, says Bank of America
Bank of America has initiated coverage of Supernus Pharmaceuticals (NASDAQ:SUPN) with a 'buy' rating and a $47 price target, arguing that its merger with Indivior creates a larger business with stronger earnings potential. The combined group has a broader portfolio of treatments for nervous… |
| 04 Nov 2026 | Yahoo Finance |
Supernus Pharmaceuticals (SUPN) After Its Indivior Merger Looks Undervalued
Supernus Pharmaceuticals (SUPN) just completed its all‑stock merger with Indivior Pharmaceuticals, creating Supernus, Inc., and simultaneously requested delisting of its legacy shares after multiple index removals connected to the transaction. Recent trading tells a mixed story for Supernus… |
| 03 Nov 2026 | Yahoo Finance |
Supernus Pharmaceuticals (SUPN) Stock May Be Undervalued After ONAPGO Exclusivity
Supernus Pharmaceuticals has had a mixed share price journey, with the stock up strongly over three years but weaker over the past year. That puts fresh attention on what investors are paying for its current level of sales. With new products, a merger closing and a changing revenue mix all in play… |
| 03 Nov 2026 | Yahoo Finance |
What Changes For Supernus Pharmaceuticals (SUPN) After Its Nasdaq Delisting And Merger?
Supernus Pharmaceuticals (NasdaqGM:SUPN) has completed its merger of equals with Indivior Pharmaceuticals, forming a combined specialty pharma business. As part of the transaction, Supernus shares have been delisted from Nasdaq, with equity now rolling into the new merged entity. The deal includes… |
| 02 Nov 2026 | Yahoo Finance |
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipelineSignificantly enhances cash flow profile and scale, unlocking greater capacity to… |
| 02 Nov 2026 | Yahoo Finance |
Why Indivior Pharmaceuticals Stock Topped the Market Today
The company is merging with a peer. |
| 31 Oct 2026 | Yahoo Finance |
SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 2026, with sales up 18.1% year on year to $226.8 million. The company’s full-year revenue guidance of $887.5 million at the midpoint came in 1.5% above analysts’ estimates. Its… |
| 30 Oct 2026 | Yahoo Finance |
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround Narrative
Indivior Pharmaceuticals (INDV) moved back into focus after reporting record third quarter earnings and reaffirming its 2026 revenue outlook. This gave investors fresh numbers to weigh alongside an approved merger with Supernus Pharmaceuticals. Over the past year Indivior Pharmaceuticals has… |
| 30 Oct 2026 | Yahoo Finance |
Supernus (SUPN) Q3 2026 Earnings Call Transcript
Qelbree prescriptions surged 18% as revenue hit $226.8 million ahead of Indivior merger. |
| 30 Oct 2026 | Yahoo Finance |
Supernus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Moby summary of Supernus Pharmaceuticals, Inc.'s Q3 2026 earnings call… |
| 30 Oct 2026 | Yahoo Finance |
Indivior Pharmaceuticals (INDV) Shareholders Back Merger After Record Third Quarter
Indivior Pharmaceuticals (NasdaqGS: INDV) reported record third quarter results, highlighting its strongest Q3 performance to date. Shareholders approved a merger with Supernus Pharmaceuticals that will see the combined business operate under the Supernus brand. The transaction is expected to close… |
| 29 Oct 2026 | Yahoo Finance |
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +89.80% and +1.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 29 Oct 2026 | Yahoo Finance |
Supernus Pharmaceuticals (NASDAQ:SUPN) delivers impressive Q3 2026, full-year sales guidance is optimistic
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 18.1% year on year to $226.8 million. The company’s full-year revenue guidance of $887.5 million at the midpoint came in 1.5% above analysts’ consensus… |
| 29 Oct 2026 | Yahoo Finance |
Supernus Announces Third Quarter 2026 Financial Results
Record total revenues of $226.8 million in the third quarter 2026, an 18% increase compared to same period last year.Combined revenues of the Company's four growth products increased to $192.2 million in the third quarter 2026, representing an increase of 29% compared to the same period last year.… |
| 29 Oct 2026 | Yahoo Finance |
Supernus Pharmaceuticals Q3 Earnings Call Highlights
Supernus Pharmaceuticals (NASDAQ:SUPN) reported record third-quarter revenue and higher sales across its growth portfolio, while management said its planned merger with Indivior Pharmaceuticals is expected to close Nov. 2 following shareholder approvals. Total revenue rose 18% year over year to $22… |
| 29 Oct 2026 | Yahoo Finance |
Supernus: Q3 Earnings Snapshot
(AP) — Supernus Pharmaceuticals Inc. (SUPN) on Thursday reported profit of $20… |
| Show more | ||
| TTM Dividend Yield | 27.84% |
| Expected Next Dividend Payment | Nov 2027 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 03 Nov 2026 | 16 Sep 2026 | 06 Nov 2026 | 8.13 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2026 | 8.13 | 1 | 27.84 |
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |